Stock screener

IMVT

Conviction 82HealthcareScan · Thu, Jun 25, 2026
IMVT$38.24+0.04%
ResistanceSupportVol 14Insider sell
63 bars
2
4
2
4
Vol MA14 1.61M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Immunovant, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.immunovant.com
Price38.24
Change+0.04%
Gap+0.99%
Rel volume1.12×
Avg volume1.66M
Avg $ vol56.46M
SMA 2033.74
SMA 5030.95
SMA 20025.16
Price vs 50+23.55%
Price vs 200+51.99%
MA stackbullish
50/200 cross
Supertrendup · 33.68
RSI (14)71
MACD hist0.48
MACD crossbull · 5d
Stoch %K / %D89 / 89
ADX (14)33
+DI / −DI38 / 10
RSI divergence
MACD divergence
ATR %+4.33%
ADR %4.49%
52w high38.24
52w low14.69
From 52w high+0.00%
Above 52w low+160.28%
New 52w highYes
SqueezeOff
Bollinger width29.30%
%B0.95
Donchian pos88.93%
Donchian high39.23
Donchian low30.24
AVWAP (52w high)38.47
vs AVWAP high-0.60%
AVWAP (52w low)24.79
vs AVWAP low+54.26%
OBV trendUp
Chaikin MF (20)0.18
Today vs 20d1.12×
Avg vol (14d)1.61M
Avg vol (20d)1.66M
Avg $ vol (20d)56.46M
Market cap7.85B
RS 3m (vs SPY)+48.06%
RS 6m (vs SPY)+35.52%
RS line new highYes
Trend template8/8
Technical rank91.1
1 week+10.16%
1 month+13.02%
3 months+54.42%
6 months+38.83%
1 year+138.97%
YTD+47.57%
P/E-15.53
P/B9.21
P/S
P/FCF-19.27
EPS-2.77
Div yield
ROE-59.30%
ROA-52.83%
Debt/Eq
Current9.09
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-22.17%
Price target46.33
Target upside21.17%
Analyst ratingBuy
Institutional58.15%
Ent. value6.95B
Revenue
Net income-110.64M
Gross profit
Free cash flow-407.32M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out205.31M
Employees315
ListedFri, Jun 21, 2019
Free float79.09M
Float %38.9%
Short interest19.21M
Days to cover5.0d
Short volume61.1%
Squeeze score81 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.73 vs −$0.60
Last surprise-21.7% miss
Setup gradeA
Conviction82 / 100
Pattern quality
Tech rank91.1 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance34.59
Support26.26
Days since event
Candle confirm
News sentiment

Financials as of Wed, Dec 31, 2025 · quarterly.

Congress activity

Disclosed STOCK Act trades in IMVT

All disclosures →
No recent disclosed trades by Congress in IMVT. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in IMVT · 3 buys · 7 sells

InsiderSideShares
Van Tuyl Christopher
Chief Legal Officer · Common Stock · 2026-06-18
Sell2.63K
Fromkin Andrew J.
Director · Common Stock · 2026-05-28
Sell210.47K
Fromkin Andrew J.
Director · Stock Option (right to buy) · 2026-05-28
Exercise31.67K
Fromkin Andrew J.
Director · Common Stock · 2026-05-28
Exercise16.26K
Fromkin Andrew J.
Director · Common Stock · 2026-05-28
Exercise31.67K
Fromkin Andrew J.
Director · Common Stock · 2026-05-28
Exercise77.18K
Fromkin Andrew J.
Director · Stock Option (right to buy) · 2026-05-28
Exercise16.26K
Fromkin Andrew J.
Director · Stock Option (right to buy) · 2026-05-28
Exercise71.49K
Fromkin Andrew J.
Director · Common Stock · 2026-05-28
Sell11.48K
Fromkin Andrew J.
Director · Stock Option (right to buy) · 2026-05-28
Exercise77.18K

SEC filings

EDGAR filings in IMVT · 1 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.